Home

GENFIT S.A. - American Depositary Shares (GNFT)

3.9850
-0.3450 (-7.97%)
NASDAQ · Last Trade: Sep 22nd, 11:24 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Earnings Scheduled For September 22, 2025benzinga.com
Via Benzinga · September 22, 2025
Dow Hits Record High As Fed Cuts Rates: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zonebenzinga.com
The CNN Money Fear and Greed index improved while remaining in the Greed zone on Friday. Dow and S&P 500 rose, Nasdaq surged.
Via Benzinga · September 22, 2025
Globus Maritime, Firefly Aerospace And 3 Stocks To Watch Heading Into Mondaybenzinga.com
U.S. stock futures down, Firefly Aerospace, PRA Group, Genfit, Globus Maritime, & Marygold Companies in focus.
Via Benzinga · September 22, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 18, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · April 28, 2025
Earnings Scheduled For April 24, 2025benzinga.com
Via Benzinga · April 24, 2025
Analyst Expectations for Genfit's Futurebenzinga.com
Via Benzinga · July 3, 2023
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2benzinga.com
Via Benzinga · April 10, 2025
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · April 10, 2025
Baidu, XPeng And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 14, 2024
Top 4 Health Care Stocks That May Keep You Up At Nightbenzinga.com
Via Benzinga · September 24, 2024
Why Nike Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · September 20, 2024
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvobenzinga.com
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.
Via Benzinga · June 11, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 31, 2024
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · May 31, 2024
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Via Benzinga · May 31, 2024
Earnings Scheduled For April 4, 2024benzinga.com
Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion.
Via Benzinga · April 4, 2024
Why CymaBay Morphed From Dollar Stock To Biotech Rocketinvestors.com
The company is working on the first treatment that could make a difference in the itching associated with a liver disease.
Via Investor's Business Daily · December 28, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 14, 2023
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Runninginvestors.com
The company is working on a treatment for a liver disease that can cause severe itching.
Via Investor's Business Daily · September 8, 2023
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Businessbenzinga.com
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of 
Via Benzinga · July 13, 2023
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Classbenzinga.com
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC: 
Via Benzinga · June 30, 2023
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patientsbenzinga.com
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) 
Via Benzinga · June 30, 2023
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · June 30, 2023
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarketbenzinga.com
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
Via Benzinga · June 30, 2023